BiotechTube

DRL_RI (Proposed rituximab biosimilar)

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Follicular Lymphoma

Conditions

Follicular Lymphoma

Trial Timeline

May 15, 2019 → Feb 27, 2023

NCT ID
NCT03976102

About DRL_RI (Proposed rituximab biosimilar)

DRL_RI (Proposed rituximab biosimilar) is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Follicular Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03976102. Target conditions include Follicular Lymphoma.

What happened to similar drugs?

1 of 20 similar drugs in Follicular Lymphoma were approved

Approved (1) Terminated (5) Active (14)
✅Obinutuzumab + Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone/Prednisolone/Methylprednisolone + VincristineRocheApproved
🔄CT-P10 + RituxanCelltrionPhase 3
🔄Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
❌Zandelisib + Rituximab + Bendamustine + CHOPKyowa KirinPhase 3
🔄Epcoritamab + Rituximab + LenalidomideAbbViePhase 3
🔄Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + BendamustineAbbViePhase 3
🔄Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03976102Phase 3Completed

Competing Products

20 competing products in Follicular Lymphoma

See all competitors
ProductCompanyStageHype Score
EnzastaurinEli LillyPhase 2
35
CT-P10 + RituxanCelltrionPhase 3
40
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + PrednisoneCelltrionPhase 3
40
TazemetostatEisaiPre-clinical
30
Zandelisib + Rituximab + Bendamustine + CHOPKyowa KirinPhase 3
32
Pirtobrutinib + MosunetuzumabEli LillyPhase 2
42
fludarabine + rituximab + VELCADEJohnson & JohnsonPhase 2
27
SHR2554Jiangsu Hengrui MedicinePhase 2
42
Epcoritamab + RituximabAbbViePhase 2
42
Epcoritamab + Rituximab + LenalidomideAbbViePhase 3
44
Ibrutinib + VenetoclaxAbbViePhase 1/2
32
Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + BendamustineAbbViePhase 3
47
Venetoclax + Bendamustine + RituximabAbbViePhase 2
35
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
47
Gonal-F (Follitropin alfa)MerckPre-clinical
26
Eltrombopag and VorinostatMerckPhase 2
27
Recombinant-follicle stimulating hormone (r-FSH)MerckPre-clinical
18
Acalabrutinib + PembrolizumabMerckPhase 1/2
32
Rituximab + Autologous dendritic cells + GM-CSF + PembrolizumabMerckPhase 2
35